Skip to main content

Advertisement

SpringerLink
Log in

Classical dopamine agonists

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson’s disease (PD) with l-DOPA and subsequently dopaminergic drugs. Parenteral apomorphine has a short lasting effect in PD, bromocriptine can be administered orally and has a long-lasting effects but is poorly tolerated. Lisuride on the other hand has a high affinity to DA receptors and can be administered orally, parenterally or via the transdermal route of administration. Last but not least Carlsson developed the concepts of presynaptic effects of DA agonists as well as DA partial agonism potentially innovative mechanisms for treatment of PD and schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andén NE, Rubenson A, Fuxe K, Hökfelt T (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19:627–629

    Article  PubMed  Google Scholar 

  • Birkmayer W, Riederer P (1983) Effects of lisuride on motor function and psychic behaviour. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 453–461

    Google Scholar 

  • Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, Hacksell U (2011) In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 118:1523–1533

    Article  CAS  PubMed  Google Scholar 

  • Calne DB, Teychenne PF, Claveria LF, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in Parkinson’s disease. Br Med J 5942:442–444

    Article  Google Scholar 

  • Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490–493

    CAS  PubMed  Google Scholar 

  • Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Dahlstroem A, Fuxe K, Lindquist M (1962) Histochemical and biochemical detection of monoamine release from brain neurons. Life Sci 4:809–8016

    Article  Google Scholar 

  • Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1980) Size reduction of a prolactin-secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol (Oxf) 12:47–51

    Article  CAS  Google Scholar 

  • Elenkova A, Shabani R, Kalinov K, Zacharieva (2012) Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 167:17–25

    Article  CAS  PubMed  Google Scholar 

  • Ernst AM (1965) Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia 21:391–399

    Article  Google Scholar 

  • Feser J (1873) Die in neuester Zeit in Anwendung gekommen Arzneimittel; Z Prakt. Veterinärwissenschaft 273, 306, quoted from R. Magnus, 1920

  • Flückiger E, Wagner HR (1968) 2-Br-alpha-Ergocryptin: Einfluss auf Fertilität und Laktation der Ratte. Experientia 24:1130–1131

    Article  PubMed  Google Scholar 

  • Fuxe K, Corrodi H, Hökfelt T, Lidbrink P, Ungerstedt U (1974) Ergocornine und 2-Br-alpha-ergocryptine: evidence for prolonged dopamine receptor stimulation. Med Biol 52:121–132

    CAS  PubMed  Google Scholar 

  • Gessa GL (1988) Agonist and antagonist effects of lisuride: electrophysiological evidence. J Neural Transm Suppl 27 201–210. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease, Springer Wien, New York

    Google Scholar 

  • González-Maeso J, Weisstaub NY, Zhou M, Chan P, Iric L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogen signalling in cortical neurons. Neuron 53:439–452

    Article  CAS  PubMed  Google Scholar 

  • Gräf KJ, Neumann F, Horowski R (1976) Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98:598–605

    Article  PubMed  Google Scholar 

  • Herzog A, Minne H, Ziegler R (1989) Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine. BMJ 298:1315

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofmann CH, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80–86

    Article  CAS  PubMed  Google Scholar 

  • Horowski R (1983) Pharmacological effects of lisuride. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 127–139

    Google Scholar 

  • Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36:373–383

    Article  CAS  PubMed  Google Scholar 

  • Horowski R, Marsden CD, Obeso JA (1988) Continuous dopaminergic stimulation: state of the art and outlook. J Neural Transm Suppl 27:249–252. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. Springer Wien, New York

  • Horowski R, Dorow R, Löschmann P-A, Runge I, Wachtel H, Obeso JA (1989) Oral and parenteral use of lisuride in Parkinson’s disease. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy of Parkinson’s disease. Springer Wien, New York, pp 269–276

    Chapter  Google Scholar 

  • Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine—a review. Psychopharmacology 95:433–446

    Article  CAS  PubMed  Google Scholar 

  • Jähnichen S, Horowski R, Pertz HH (2006) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Clin Neuropharmacol 29:80–86

    Article  PubMed  Google Scholar 

  • Jurasz A (1875) Über die Wirkungen des salzsauren Apomorphins Dt. Arch Klin Med 16:41 (quoted from R. Magnus 1920)

    Google Scholar 

  • Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43:2–11

    Article  CAS  PubMed  Google Scholar 

  • Lange KW, Löschmann PA, Wachtel H, Horowski R, Jähnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212:247–252

    Article  CAS  PubMed  Google Scholar 

  • Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R (1978) Lisuride hydrogen maleate: evidence for a long-lasting dopaminergic activity in humans. J Clin Endocrinol Metab 46:196–202

    Article  CAS  PubMed  Google Scholar 

  • Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659

    Article  CAS  PubMed  Google Scholar 

  • Löschmann PA, Horowski R, Wachtel H. Bromerguride - an ergoline derivative with atypical neuroleptic properties. Clin Neuropharmacol (1992)15(Suppl 1 Pt A):263A–264A

    Article  PubMed  Google Scholar 

  • Luquin MR, Obeso JA, Martínez-Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1987) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45:561–568

    CAS  PubMed  Google Scholar 

  • MacLeod RM, Lehmeyer JE (1974) Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94:1077–1085

  • Matthiesen A, Wright CRA (1869) Proc R Soc 17:455–460 (quoted from R. Magnus 1920)

    Article  Google Scholar 

  • McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Parenteral administration of lisuride in Parkinson’s disease. Eur Neurol 22:240–255

    Article  CAS  PubMed  Google Scholar 

  • Pieri L, Keller HH, Burkard W, da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–279

    Article  CAS  PubMed  Google Scholar 

  • Rehse K (1978) Neuropsychotrope Aktivität und Toxizität von Oxidationsprodukten des Apomorphin. Arch Pharm 311:360–363

    Article  CAS  Google Scholar 

  • Seemann D, Danielczyk W, Ogris E, Jellinger K, Riederer P (1984) Dopaminergic agonists—effects on multiple receptor sites in Parkinson’s disease. In: Callaghan N, Galvin R (eds) Recent research in neurology. Pitman, Chichester, pp 49–60

    Google Scholar 

  • Stocchi F (2008) Use of apomorphine in Parkinson’s disease. J Neurol Sci 29(Suppl 5):383–386. https://doi.org/10.1007/s10072-008-1053-8

    Article  Google Scholar 

  • Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Subcutaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm Suppl 27:27–33

    Google Scholar 

  • Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125:2058–2066

    Article  PubMed  Google Scholar 

  • Struppler A, Von Uexkull T (1953) Untersuchungen zum Wirkungsmechanismus von Apomorphin auf den Parkinson-Tremor. Z Klin Med 152:46–57

    CAS  PubMed  Google Scholar 

  • Svensson K, Eriksson E, Carlsson A (1993) Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32:1037–1045

    Article  CAS  PubMed  Google Scholar 

  • Weil C (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 10:172–195

    Article  CAS  PubMed  Google Scholar 

  • Woitalla D, Müller T, Benz S, Horowski R, Przuntek H (2004) Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl 68:89–95

    Google Scholar 

  • Wuttke W, Cassell E, Meites J (1971) Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF. Endocrinology 88:737–741

    Article  CAS  PubMed  Google Scholar 

  • Zikán V, Semonský M (1960) Mutterkornalkaloide XVI. Einige N-(d-6-methylisoergolenyl-8)-, N-(d-6-methylergolenyl-8)- und N-(d-6-methylergolin(I)-yl-8)-N′-substituierte Harnstoffe. Collect Czech Chem Commun 25:1922–1928

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Antaxios GmbH, Zum Weiher 44, 14552, Wildenbruch, Germany

    R. Horowski

  2. Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany

    P.-A. Löschmann

Authors
  1. R. Horowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P.-A. Löschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Horowski.

Additional information

Dedicated to the memory of the great neuroscientist Arvid Carlsson (25-01-1923–26-06-2018) whose discoveries became the basis for many important new therapies. (If we honour a great man, we are honouring ourselves B. Brecht).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horowski, R., Löschmann, PA. Classical dopamine agonists. J Neural Transm 126, 449–454 (2019). https://doi.org/10.1007/s00702-019-01989-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-019-01989-y

Keywords

Search

Navigation